Makenna Delaney & Sullivan, Inc. to assist the firm.
W. Richard Ulmer
MAKENNA DELANEY & SULLIVAN
IRVINE — June 8, 1998 – InVitro International, (OTC Bulletin Board: INVI) announced today that it has signed Makenna Delaney & Sullivan, Inc. to assist the firm with investor relations, capital formation, and related materials. InVitro has publically announced its intention to merge with entities in related technology fields, and has specifically targeted Miragen, Inc. Miragen, Inc. has developed a cost-effective, patented, biologically based identification system for use in several markets, including human clinical laboratories, animal, forensic, educational, and environmental applications.
For more than nine years, Makenna Delaney & Sullivan has specialized in investor relations, venture packaging, equity financing, strategic marketing, financial documentation, and corporate identity services. MDS is a nationally recognized leader in business document production and investor relations with a successful track record of assisting clients in their quest for capital.
InVitro International is engaged in the development, manufacture and sale of quality, proprietary preventive products and services to ensure the safekeeping of humans and the environment, and to minimize animal testing in commercial and academic enterprise.
InVitro International offers experience and consulting from what may be the world’s largest data base of NON-ANIMAL ocular and dermal test results; this offering is part of INVI’s Irritection Assay Systemr (IAS) and Corrositexr Assay methods. The IAS is a plate reader based computer driven upgrade from the former Eytex/Skintex methodology; it has been widely accepted over the past two years and has helped reduce industry costs when testing for safety and efficacy of ocular, skin care, personal care, and chemical products. InVitro International offers industry a series of services, including protocol development, customized contract testing services, and direct kit sales in support of product claims or workplace safety. The Irritection Assay System is well suited for choosing new formulations as well as testing final or competitive products. IAS helps cut time and costs out of new product development cycles.
Certain information in this document includes “forward-looking statements” within the meaning of applicable securities laws. In addition, from time to time the Company or its executive officers have made or may make forward-looking statements, orally or in writing, that involve substantial risks and uncertainties. Actual results could differ materially from those projected or suggested by any forward-looking statements as a result of a variety of factors and conditions including, but not limited to, the ability of the Company to continue as a going concern, market acceptance of new products and technologies, economic, competitive, governmental, and technological factors affecting the Company’s operations, markets, services, and prices, significant disruptions caused by third parties’ failure to address Year 2000 issues, litigation costs, changes in the Company’s operations, unanticipated events and various other factors. The reader is specifically referred to disclosures contained in this document and in prior documents publicly disseminated by the Company.